Keros Therapeutics Announces Preliminary Results of Tender Offer

Core Points - Keros Therapeutics, Inc. announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of common stock at a fixed price of $17.75 per share, totaling approximately $194.4 million [1][3] - The tender offer expired on November 18, 2025, and was part of a previously announced $375 million capital return program [1] - A total of approximately 16,659,732 shares were validly tendered, with an additional 1,186,829 shares tendered through notice of guaranteed delivery [2] Tender Offer Details - Keros expects to accept for payment 10,950,165 shares on a pro rata basis due to the oversubscription of shares tendered [3] - The shares to be acquired represent approximately 35.91% of Keros' outstanding common stock as of the expiration date [3] - The final number of shares purchased will be confirmed after the completion of the confirmation process by the Depositary [4] Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [6] - The company is recognized for its understanding of TGF-ß proteins, which are crucial for the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, addresses cytopenias in myelodysplastic syndrome and myelofibrosis patients [6]